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Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian stimulation (COS)
as part of assisted reproductive technologies (ART). While the safety and efficacy of ART is well established,
physicians should always be aware of the risk of OHSS in patients undergoing COS, as it can be fatal. This article will
briefly present the pathophysiology of OHSS, including the key role of vascular endothelial growth factor (VEGF), to
provide the foundation for an overview of current techniques for the prevention of OHSS. Risk factors and
predictive factors for OHSS will be presented, as recognizing these risk factors and individualizing the COS protocol
appropriately is the key to the primary prevention of OHSS, as the benefits and risks of each COS strategy vary
among individuals. Individualized COS (iCOS) could effectively eradicate OHSS, and the identification of hormonal,
functional and genetic markers of ovarian response will facilitate iCOS. However, if iCOS is not properly applied,
various preventive measures can be instituted once COS has begun, including cancelling the cycle, coasting,
individualizing the human chorionic gonadotropin trigger dose or using a gonadotropin-releasing hormone (GnRH)
agonist (for those using a GnRH antagonist protocol), the use of intravenous fluids at the time of oocyte retrieval, and
cryopreserving/vitrifying all embryos for subsequent transfer in an unstimulated cycle. Some of these techniques
have been widely adopted, despite the scarcity of data from randomized clinical trials to support their use.
Keywords: Ovarian hyperstimulation syndrome, Individualized controlled ovarian stimulation, Risk factors, Vascular
endothelial growth factor, PreventionBackground
There has been a rapid increase in the number of
couples receiving treatment for infertility with assisted
reproductive technology (ART) in recent years [1]. While
there is robust evidence supporting the efficacy and
safety of ART, it is important to be aware of the risks,
the most serious of which is ovarian hyperstimulation
syndrome (OHSS). OHSS is a rare, iatrogenic complica-
tion of controlled ovarian stimulation (COS). Severe
OHSS occurs in approximately 1.4 % of all cycles [2],
affecting approximately 6020 patients per year in the
United States and Europe [3]. The mortality risk is esti-
mated to be 1 in 450000 to 500000 cases [4].* Correspondence: diego.ezcurra@emdserono.com
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distribution, and reproduction in any mediumPathophysiology and symptoms of OHSS
OHSS is an exaggerated response to COS characterized
by the shift of protein-rich fluid from the intravascular
space to the third space, mainly the abdominal cavity
that occurs when the ovaries become enlarged due to
follicular stimulation [5]. This shift in fluid is due to
increased vascular permeability in response to stimula-
tion with human chorionic gonadotropin (hCG) [5].
Prostaglandins, inhibin, the renin-angiotensin-aldosterone
system and inflammatory mediators have all been impli-
cated in the aetiology of OHSS [6]; however, vascular
endothelial growth factor (VEGF) has been identified as
the major mediator (Figure 1) [5]. The expression of VEGF
and VEGF receptor 2 (VEGFR-2) mRNA increases signifi-
cantly in response to hCG, and peak levels coincide with
maximum vascular permeability [5].
The clinical manifestations of OHSS reflect the extent
of the shift of fluid into the third space and the resultingentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,

































Figure 1 The pathogenesis of OHSS. Human chorionic gonadotropin (hCG) stimulates a high number of granulosa-lutein cells leading to the
increased production of vascular endothelial growth factor (VEGF) mRNA (Figure 1A); VEGF receptor-2 (VEGFR-2) mRNA production in the
granulosa-lutein and endothelial cells is also increased in response to hCG. High amounts of VEGF are produced and released from the granulosa-
lutein cells and bind to VEGFR-2 on the endothelial cell membranes. Downstream signaling augments vascular permeability (Figure 1B). Adapted
from Soares et al [7].
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tion. Symptoms range from mild abdominal distention
due to enlarged ovaries alone or with an accompanying
fluid shift into the abdomen, to renal failure and death as
a result of hemoconcentration and reduced perfusion of
organs such as the kidneys, heart and brain (Table 1)
[5,8]. Indeed, as the severity of OHSS increases, so does
the number of organs affected [8].
OHSS can be “early” or “late” based on the source of
hCG. Early OHSS occurs in the luteal phase of COS after
the administration of exogenous hCG to induce oocyte
maturation. Late OHSS occurs when ART results in
pregnancy and is the consequence of an increase in
endogenous hCG levels following conception. In most
cases, OHSS is self-limiting and resolves spontaneously
within several days. However, OHSS may persist, particu-
larly late OHSS due to pregnancy.
Risk factors/biomarkers for OHSS
Several primary and secondary risk factors for OHSS
have been identified (Table 2). However, their sensitivityand specificity for predicting hyper-response/OHSS is
variable [10,11]. Despite this, as indicators of risk, these
risk factors/biomarkers assist in the identification of
patients that require individualized COS (iCOS).
There are a number of well-established primary risk
factors for the development of OHSS, including young
age, polycystic ovary syndrome (PCOS) – characterized
by ultrasound and the ratio of luteinizing hormone (LH)
to follicle stimulating hormone (FSH) – and a history of
an elevated response to gonadotropins, i.e. prior hyper-
response/OHSS [9,10,15]. Studies investigating the
impact of low body weight/body mass index (BMI) on
the development of OHSS report contradictory results
[12,15]. Therefore, body weight/BMI does not currently
appear to be a useful marker for increased risk of OHSS.
Immunological sensitivity, i.e. hypersensitivity or allergies
may also be predictive of OHHS. In a prospective cohort
study, patients who developed severe OHSS (n = 18/428)
had an increased prevalence of allergies (56 % vs. 21 % in
the control group) [16]. While a link between OHSS and
allergy is plausible, as the pathophysiological changes in
Table 1 Classification of OHSS symptoms [5] (adapted
from Navot et al [9])













Severe Mild and moderate features + Hemoconcentration
(Hct >55 %)
Clinical evidence of ascites WBC >25000
Hydrothorax CrCl <50 mL/min
Severe dyspnea Cr >1.6
Oliguria/anuria Na+ <135 mEq/L
Intractable nausea/vomiting K+ >5 mEq/L
Tense ascites Elevated liver enzymes
Low blood/central venous pressure











Adult respiratory distress syndrome
Sepsis
Cr = serum creatinine level; CrCl = creatinine clearance; WBC=white blood cell
count.
Table 2 Risk factors/predictive factors for OHSS (adapted
from Humaidan et al [10])
Risk factor Threshold of risk
Primary risk factors (patient related)
• High basal AMH - >3.36 ng/mL independently
predicts OHSS [12]
• Young age - <33 years predicts OHSS [12]
• Previous OHSS - Moderate and severe cases,
particularly those with
hospitalization
• PCO like ovaries - >24 antral follicles in both ovaries
combined
Secondary risk factors (ovarian response-related)
On day of hCG trigger
• High number of medium/
large follicles
- ≥13 follicles ≥11 mm in diameter
[14]
- >11 follicles ≥10 mm in
diameter [12]
• High or rapidly rising E2 levels
and high number of follicles
- E2 5,000 ng/L and/or ≥18 follicles
predictive of severe OHSS [14]
• Number of oocytes retrieved - >11 predicts OHSS [12]
• VEGF levels - Not applicable
• Elevated inhibin-B levels - Elevated levels on day 5 of
gonadotropin stimulation,
at oocyte retrieval and 3
days before
• hCG administration for LPS - Not applicable
• Pregnancy (increase in
endogenous hCG)
- Not applicable
AFC = antral follicle count; AMH= anti-Müllerian hormone; E2 = estradiol;
hCG=human chorionic gonadotropin; LPS = luteal phase support;
OHSS = ovarian hyperstimulation syndrome; PCOS = polycystic ovary syndrome;
VEGF = vascular endothelial growth factor.
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matory response, the influence of allergies on the devel-
opment of OHSS requires further study.
Research has identified additional hormonal biomar-
kers that may also predict a patient’s response to COS
and determine their risk of OHSS. In the very early fol-
licular phase of the cycle, a number of antral follicles (2–
10 mm in size) are present that are easily detected by
transvaginal ultrasound as their appearance is marked by
the formation of a fluid-filled cavity adjacent to the oo-
cyte (the antrum) [11,12]. The number of small antral
follicles at the beginning of a cycle is related to age and
may reflect the ovarian reserve [11,12]. In a study byKwee et al, an antral follicle count (AFC) >14 had the
highest sensitivity (82 %) and specificity (89 %) to posi-
tively predict ovarian hyper-response [13].
Basal Anti-Müllerian hormone (AMH) levels prior to
COS have also been shown to be predictive for OHSS
[17]. Two recent, prospective, randomized controlled
trials (RCTs) in large cohorts demonstrated that
basal AMH levels ~≥3.5 ng/mL were predictive of
hyper-response/OHSS with high sensitivity and specifi-
city [12,18]. Moreover, AMH may be a better predictive
marker of excessive ovarian response to COS than age,
basal FSH, and estradiol (E2) on the day of hCG admin-
istration (see below), and has been shown to be at least
as good as AFC [12,17-19]. Furthermore, AMH predicts
ovarian response independently of age and PCOS [18].
Activating mutations in the FSH receptor (FSHR) gene
have been shown to confer a higher response to FSH and
therefore FSHR genotype may predispose women to
OHSS [20], Although FSHR genotype cannot predict the
risk of iatrogenic OHSS at present, it may be used to
predict the severity of the condition. Furthermore, muta-
tions in the bone morphogenic protein-15 (BMP-15)
Fiedler and Ezcurra Reproductive Biology and Endocrinology 2012, 10:32 Page 4 of 10
http://www.rbej.com/content/10/1/32gene may predict ovarian hyper-response and OHSS, but
further research is required.
Traditionally, high or rapidly rising serum E2 levels on
the day of the hCG trigger, denoting oversensitivity to
hCG, was used as a predictor of OHSS [11]. However,
high E2 levels alone are poor predictors of OHSS
[3,10,11]. The number of follicles in combination with
serum E2 levels predicts OHSS with high sensitivity and
specificity [14]. Despite E2 levels alone being poor
predictors of OHSS, they are often closely monitored
and used to drive secondary OHSS prevention strategies.
Preventing OHSS with iCOS
Prevention of OHSS is a multi-stage process. The key to
the primary prevention of OHSS during COS is recog-
nizing risk factors and individualizing the ovarian stimu-
lation protocol appropriately using iCOS [17,21]. iCOS
should aim to reduce the cycle cancelation rate and the
iatrogenic complications of COS, including OHSS, and is
key to improving ART outcomes [18,21]. Based on a
retrospective study of 1378 patients, basal FSH, BMI, age
and number of follicles <11 mm at screening were
reported to be the main predictive factors for ovarian
response [22]. The implementation of an algorithm
(CONSORT) to include these risk factors has been
proposed which would inform the choice of starting
gonadotropin dose [23].
Such a personalized approach, where even clomiphene
citrate with human menopausal gonadotropin or FSH
[24] can have a place [25], allows the appropriate treat-
ment to be selected and adapted for each patient and
avoids the increased risks that may result from assigning
standardized treatment to patient groups (for example,
designating doses by weight category). The use of effect-
ive biomarkers could be the ultimate tool to drive iCOS.
This could potentially comprise a routine diagnostic test
performed before COS to predict ovarian response and
facilitate iCOS by determining the required stimulatory
gonadotropin dose [10], thereby avoiding possible
complications, including OHSS.
The use of AMH, as a biomarker to individualize COS
protocols, has been evaluated in a retrospective study of
women undergoing ART [26]. The study compared 346
women using conventional COS with 423 women treated
using COS protocols tailored to the level of AMH.
The analysis reported increased embryo transfer
rates (79–87 %, P = 0.002), pregnancy rate per cycle
(17.9–27.7 %, P = 0.002) and live birth rate (15.9–23.9 %,
P = 0.007) in those women on AMH-tailored protocols
compared with conventional COS. The study also
reported a fall in the incidence of OHSS (96.9–2.3 %,
P = 0.002) and failed fertilization (7.8 %–4.5 %, P = 0.066).
In the future, pharmacogenetics could also be used to
direct iCOS [20].Before initiating iCOS, patients at high risk of OHSS
can be identified from their risk/biomarker profile and
the stimulation protocol can be tailored to their needs
through iCOS. If iCOS is not correctly applied then
patients are more likely to experience OHSS. To
minimize the risk of severe complications, secondary
preventative measures are normally applied. Various
preventative protocols have been proposed to reduce or
minimize the risk of developing OHSS during COS,
including in vitro oocyte maturation, coasting,
decreasing the hCG trigger dose, and using a gonadotropin-
releasing hormone agonist (GnRHa) trigger. However,
despite the widespread use of these preventative techniques,
supporting evidence is limited.
There have been few RCTs that fully evaluate the
efficacy and safety of these protocols [10], with different
centers tending to favor specific techniques based on
their own experience.
A recent Cochrane review concluded that there was no
evidence to suggest a benefit of coasting to prevent
OHSS compared with no coasting or other interventions,
but only four of 16 studies included in the review met
the RCT inclusion criteria [27]. Despite the lack of data
from RCTs to support its use for the reduction of OHSS
[27], coasting has been widely adopted. However, coast-
ing is not an option with the newer, long-acting follicular
stimulants, such as the recombinant glycoprotein corifol-
litropin alfa (ELONVAW; MSD).
Due to its long half-life (65 hours), a single injection of
corifollitropin alfa is intended to replace daily gonado-
tropin injections during the first week of COS [28,29]. In
two phase 3 trials investigating corifollitropin alfa (100
or 150 μg) as part of a GnRH antagonist COS protocol,
rates of moderate-to-severe OHSS were 3.4–4.1 %, com-
pared with 1.6–2.7 % in patients receiving recombinant
FSH [30,31]. Recently, the incidence of moderate-to-
severe OHSS in women receiving corifollitropin alfa
(150 μg) was shown to be 1.8 % in a multicenter, open-
label, uncontrolled phase 3 study using a multidose an-
tagonist protocol. First, second and third COS cycles
were started by 682, 375 and 198 patients, respectively.
OHSS was reported in 24 patients (3.5 %) in the first
COS cycle and in seven patients (1.9 %) in the second
cycle; it did not occur during the third treatment cycle.
A total of 15 cases of mild OHSS were reported; eight
cases were considered moderate and another eight were
classed as severe OHSS [32]. As OHSS occurred despite
the study design excluding patients at high risk of
OHSS, this may be indicative of idiosyncrasies in patient
management protocols and individual clinical practice.
Metformin has also been used for the prevention of
OHSS. In a meta-analysis of eight randomized controlled
trials of women with PCOS, metformin given 2 months
before starting COS significantly reduced the risk of
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interval [CI] 0.11–0.41, P< 0.00001) [33].Cancelling ovulation induction
As OHSS is associated with hCG, terminating the ovula-
tion cycle by cancelling the hCG trigger in the presence
of several risk factors for OHSS is the most effective
technique to prevent OHSS [15]. hCG induces the
production of VEGF, the primary mediator of OHSS [5].
However, this course of action is costly and psychologic-
ally demanding for the participants. Therefore, it is
usually reserved for patients at high risk of OHSS and
those with total loss of cycle control.
In vitro oocyte maturation, where immature oocytes
are retrieved and matured in vitro before fresh embryo
transfer, is also an option in these patients. In 56 patients
with high risk of OHSS during the controlled ovarian
hyperstimulation cycle, hCG was given when the leading
follicle reached 12–14 mm in diameter [34]. Seventy-six
percent of oocytes matured. All patients underwent fresh
embryo transfers, resulting in a clinical pregnancy rate of
46 %. There were no severe cases of OHSS. However, it
is worth noting that in vitro maturation of oocytes
remains an experimental procedure, used only in a small
number of clinics around the world.Coasting: withholding exogenous gonadotropins
Coasting is the concept of withholding exogenous gonado-
tropins and postponing the hCG trigger until a patient’s E2
level has declined to a ”safer” pre-defined level (usually
~3000 pg/nL [35,36]).
Follicular size generally correlates with the FSH thresh-
old and, therefore, larger follicles that are more resistant
to apoptosis and atresia should continue to grow when
FSH levels are declining [35]. Coasting leads to the
selective regression of the pool of immature (small/
medium) follicles, thereby reducing the functioning
granulosa cell mass available for luteinization and
resulting in a decline in vasoactive substances involved
in the pathogenesis of OHSS, including VEGF (Figure 1
[37,38]). Coasting has been shown to reduce the
incidence of OHSS in high-risk patients without affecting
cycle outcome, as demonstrated by anecdotal data and
data from non-randomized trials [3,36,38-40]. However,
coasting is becoming less of an option with the newer,
long-acting follicular stimulants, such as the recombin-
ant glycoprotein corifollitropin alfa (ELONVAW; MSD)
[36,38,39].16 % of patients had ascites and 2.5 % required
hospitalization in a systematic review of 12 studies
involving 493 patients, only one of which was a RCT
[40]. In addition, there are reports that coasting for more
than 3–4 days results in lower than anticipated preg-
nancy and implantation rates [35,36,39].Individualizing the hCG trigger dose
Theoretically, decreasing the standard dose of hCG
administered to trigger oocyte maturation (10000 IU)
might prevent OHSS. Doses of hCG as low as 3300 IU
have been shown to effectively trigger oocyte maturation
in ART without adversely affecting cycle outcome;
2000 IU was ineffective [41]. Doses of hCG as low as
2500 IU have been shown to be effective in patients with
PCOS. However, the benefit of low-dose hCG for the
prevention of OHSS is not clear, as data are sparse and
the studies that have been conducted comprised small
sample sizes, involved a small number of cycles or were
not powered to detect a difference in OHSS rate. Import-
antly, there appears to be no difference between the inci-
dence of severe OHSS with recombinant hCG compared
with urinary hCG [42].
Choice of luteal phase support
A recent Cochrane review has shown that the choice of
luteal phase support is related to the incidence of OHSS
[43]. This review included a comparison of the use of
progesterone versus hCG and progesterone, for luteal
phase support, and showed an increased risk of OHSS in
the groups taking hCG and progesterone (Peto OR 0.45,
95 % CI 0.26–0.79). The review concluded that the use
of hCG should be avoided.
Employing a dopamine agonist
Recent evidence also demonstrates that the administra-
tion of a dopamine agonist, such as cabergoline or guina-
golide, from the day of hCG trigger can reduce the
incidence of OHSS by inhibiting the phosphorylation of
VEGFR-2 in response to hCG [5,44]. To date, two rando-
mized controlled trials comparing the use of cabergoline
with intravenous albumin alone have shown that caber-
goline (0.5 mg/d) was more effective than albumin in
preventing OHSS [45,46]. In addition, one study has
shown that women with PCOS are less responsive to
cabergoline compared with those without PCOS, most
probably due to a decreased production of dopamine
and dopamine receptor expression [47]. Interestingly,
dopamine agonists cannot prevent late OHSS [5].
Employing a GnRH agonist trigger
The risk of OHSS can be reduced by using a GnRHa
trigger, instead of an hCG trigger, in patients undergoing
COS with a GnRH-antagonist protocol. Since the tech-
nique was first suggested in 1988 [48], a number of stud-
ies have investigated the efficacy and safety of a GnRHa
trigger. An analysis by Humaidan and colleagues of three
early RCTs demonstrated similar results in patients
receiving a GnRHa trigger and those receiving an hCG
trigger in terms of number of ocytes retrieved,
fertilization rate and embryo quality score [49]. However,
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comes, with a reduced likelihood of pregnancy and an
extremely high early pregnancy loss rate, which was
attributed to luteal phase insufficiency, despite standard
luteal phase support (LPS) [49]. Humaidan et al also
undertook an analysis of six subsequent RCTs using
modified LPS, which yielded similar outcomes in patients
receiving GnRHa or hCG triggers, with a non-significant
6 % difference in delivery rate in favor of an hCG trigger
[49]. Importantly, the use of a GnRHa trigger completely
eliminated OHSS in the 375 women randomized to
receive it across all nine RCTs [49], although there are
isolated reports of OHSS in patients receiving a GnRHa
trigger, particularly in those receiving adjuvant low-dose
hCG for LPS, as would be expected [50,51]. LPS strat-
egies in patients receiving a GnRHa trigger are reviewed
in detail by Engmann et al [50].
A recent Cochrane review of 11 RCTs concluded that
GnRHa should not be routinely used to trigger oocyte
maturation due to lower live birth rates and ongoing
pregnancy rates, but makes an exception for women at
high risk of OHSS, after appropriate counseling [52]. Im-
portantly, this review reported that there were no OHSS
events in the GnRHa arm of the study, a result which
compares favorably against other preventive strategies. It
is possible therefore, that combining GnRHa with
embryo vitrification has the potential to provide a good
clinical outcome [52].
While both the analysis by Humaidan et al and the
Cochrane review both support the use of a GnRHa
trigger to prevent OHSS, it should be noted that the
Cochrane review included all RCTs employing a GnRHa
trigger, irrespective of the LPS used [44]. In contrast, the
analysis by Humaidan et al analyzed the RCTs according
to LPS, and clearly demonstrated no adverse effect on
cycle outcome in patients receiving a GnRH trigger with
appropriate LPS [49]. Therefore, GnRHa now appears to
be a valid alternative to an hCG trigger for final oocyte
maturation.
Intravenous fluids at time of oocyte retrieval
Albumin has both osmotic and transport functions,
properties that underscore its potential for the preven-
tion of OHSS [53]. Conflicting data are available regard-
ing the potential benefit of intravenous (IV) albumin at
the time of oocyte retrieval to prevent OHSS. An early
Cochrane review of five RCTs clearly showed a benefit
associated with the administration of IV albumin at the
time of oocyte retrieval in patients at high risk of OHSS,
with no effect on pregnancy rate [54]. However, a recent
update to this review including eight RCTs concluded
that there was limited evidence for the benefit of IV
albumin in this setting, although there was no detrimental
effect on pregnancy rate [53]. Another recent systematicreview and meta-analysis of eight RCTs (seven common to
both analyses) made similar conclusions. In contrast, a
further systematic review and meta-analysis of nine RCTs
found that while there was no statistical benefit regarding
the rate of OHSS compared with saline/no fluids, IV
albumin significantly reduced pregnancy rates (relative risk
0.85, 95 % CI 0.74–0.98 [55]).
Hydroxyethyl starch (HES) is a plasma expander and a
possible alternative to albumin in this setting. As a non-
biological substance, HES is not associated with the
potential for viral transmission that may be present with
albumin [56]. The recent Cochrane review of studies
using IV albumin also analyzed the effects of HES at the
time of oocyte retrieval in patients at high risk of OHSS
in three RCTs [53]. HES was associated with a significant
reduction in the incidence of OHSS (OR 0.12, 95 % CI
0.04–0.40), without affecting pregnancy rates.
Cryopreservation of oocytes and embryos
Cryopreservation is considered a traditional approach for
the prevention of OHSS in COS. Oocyte retrieval and
elective cryopreservation with subsequent transfer in an
unstimulated cycle eliminates further hCG exposure in
the active cycle, avoiding the frustration of cycle
cancellation and preserving the chance for a live birth.
The pregnancy rates achieved with frozen oocytes
and embryos are now similar to those achieved in fresh
cycles [57].
Cryopreservation appears to reduce, but not eliminate,
OHSS without adversely affecting pregnancy rates [58-62].
Cryopreservation has been shown to offer a higher cumu-
lative pregnancy rate than coasting to avoid OHSS [60].
However, variations in policies exist regarding which stage
(pronucleate, cleavage stage or blastocyst) and protocol
should be used for cryopreservation, and at which stage
these should be thawed and transferred [63]. This pro-
cedure is however not without risk. In a retrospective
review of maternal death related to IVF carried out in
the Netherlands, three women with OHSS died follow-
ing ovum retrieval for cryopreservation. Two women died
as a result of adult respiratory distress syndrome and
multi-organ failure, and one due cerebrovascular throm-
bosis. All three patients had all their embryos frozen be-
cause they were exhibiting symptoms of OHSS [64].
Recently, interest in cryopreservation has increased
due to vitrification, an efficient method of cryopreserva-
tion that result in better survival after thawing, due to
reduced cellular damage compared with traditional
cryopreservation techniques [57]. Vitrification is the
rapid process of turning a liquid into an amorphous
“glass-like” substance, rather than changing it to a solid
by crystallization (i.e. the passage of a liquid to a solid
without the intermediate formation of ice crystals). Stud-
ies have shown that vitrification is associated with better
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cation of embryos has been shown to be successful for
the prevention of OHSS in high-risk women [66].
Furthermore, vitrified-warmed blastocyst transfer cycles
(n = 136) yielded higher implantation and pregnancy
rates than fresh blastocyst transfer cycles (n = 110) in a
retrospective study in China [67]. These results
prompted the authors to propose a new embryo transfer
strategy avoiding fresh transfers altogether and instead
vitrifying all blastocysts for warming and transfer in a
subsequent cycle. Similarly, in Germany a pregnancy rate
of 36.9 % was achieved with vitrification, three times
higher than that achieved with traditional cryopreserva-
tion in the same centre, which led the investigators to
ask: “is it still fair to advocate a slow freezing rate?” [68].
Given the widespread use of traditional cryopreservation
for the prevention of OHSS, and the limited but promis-
ing results with vitrification published so far, it seems
likely that vitrification will take over where traditional
cryopreservation has led.
Treatment of OHSS
If iCOS is not applied and risk reduction strategies are
unsuccessful, measures are required to minimize the
effect of OHSS and prevent further morbidity. Mild
OHSS, which due to the very nature of COS occurs in
most patients, and moderate OHSS with no clinical evi-
dence of ascites or enlarged ovaries are not associated
with complications and as a result do not require specific
treatment. Mild OHSS and moderate OHSS can be
treated symptomatically and patients monitored on an
outpatient basis [69], for example, by tracking weight
gain, which is one of the first signs of fluid retention.
Severe OHSS, on the other hand, must be regarded as a
potentially fatal complication that requires immediate
treatment to maintain circulatory volume and restore
electrolyte balance using IV fluids [69]. However, this
often leads to increased ascitic fluid formation [70].
Historically, the treatment of OHSS, comprising IV ther-
apy with or without paracentesis (aspiration of the ascitic
fluid), involved prolonged hospitalization [69-71].
Aggressive outpatient management of patients with mod-
erate-to-severe OHSS using early paracentesis has been
shown to effectively reduce the need for hospitalization
[70-73]. Both abdominal [70,71] and transvaginal [72,73]
routes for paracentesis have been shown to be effective.
Furthermore, early outpatient paracentesis for moderate-
to-severe OHSS is more cost effective than traditional
conservative inpatient therapy [74].
In patients with moderate OHSS, aggressive early
paracentesis can prevent the progression of disease
severity [75]. In addition to preventing hospitalization,
paracentesis rapidly relieves symptoms, with patients
experiencing improvements in urine output, renal functionand hematocrit levels as early as 24 hours following the
procedure [75]. Ultrasound-guided transvaginal aspiration
of ascitic fluid has also been shown to be safe and effective
in improving symptoms, preventing complications, and
shortening the hospital stay for women with severe OHSS
[76,77]. It has also been shown that early (luteal phase)
transvaginal aspiration of accumulating fluid in patients
developing intra-abdominal ascites can reduce the need
for hospitalization [71,78].
A recent review of the clinical aspects of OHSS pro-
vides detailed recommendations for management
according to patient diagnosis and risk [79].
Conclusions
Prevention of OHSS begins with tailoring an individual’s
ovarian stimulation protocol based on their risk profile,
through iCOS. Selecting one standardized preventative
approach for all patients or a large cohort of patients
undergoing COS is challenging, because the benefits and
risks associated with each strategy vary between indivi-
duals. Identification of hormonal, functional and genetic
markers of ovarian response will facilitate iCOS. Indeed,
if the risk factors and biomarkers for OHSS are recog-
nized and patients are correctly treated with iCOS,
OHSS may no longer be an issue. In the meantime,
despite the scarcity of data from RCTs to support their
use, there are various secondary preventative measures
that can be employed to reduce the risk of OHSS once
COS has begun, including canceling the cycle, coasting,
individualizing the hCG trigger dose or using a GnRH
trigger (for those using a GnRH antagonist protocol), the
use of IV fluids at the time of oocyte retrieval, and
cryopreserving/vitrifying all oocytes.
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